Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9127588 | 0.85 | LMNA (0.44) | LMNAMAPTABCB11MAPK1ATM | |
| SCHEMBL17200643 | 0.83 | LMNA (0.61) | LMNAMAPTABCB11MAPK1ATM | |
| SCHEMBL14968089 | 0.83 | LMNA (0.38) | LMNAMAPTABCB11MAPK1ATM | |
| Cyclopentane SCHEMBL11247040 | 0.80 | LMNA (0.48) | LMNAMAPTABCB11MAPK1ATM | |
| SCHEMBL15194530 | 0.80 | LMNA (0.55) | LMNAMAPTABCB11MAPK1ATM | |
| SCHEMBL14967664 | 0.80 | ALDH1A1 (0.50) | LMNAMAPTABCB11MAPK1ATM | |
| SCHEMBL1675969 | 0.80 | — | — | |
| SCHEMBL14967582 | 0.79 | CES2 (0.47) | LMNAMAPTABCB11MAPK1ALDH1A1 | |
| SCHEMBL1810872 | 0.79 | SMN1; SMN2 (0.36) | LMNAMAPTABCB11MAPK1ATM | |
| SCHEMBL8956984 | 0.79 | LMNA (0.44) | LMNAMAPTABCB11MAPK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661921-B1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NODTHERA LTD (GB) | 2023-10-18 | — | — | EP | disclosed |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2021-03-25 | — | — | US | disclosed |
| EP-3661921-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | Nodthera Limited (GB) | 2020-06-10 | — | — | EP | disclosed |
| US-10301397-B2 | Method for producing polydienes and polydiene copolymers with reduced cold flow | BRIDGESTONE CORPORATION (JP) | 2019-05-28 | — | — | US | disclosed |
| WO-2019025467-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2019-02-07 | — | — | WO | disclosed |
| US-20160340447-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9458270-B2 | Method for producing polydienes and polydiene copolymers with reduced cold flow | BRIDGESTONE CORPORATION (JP) | 2016-10-04 | — | — | US | disclosed |
| EP-2780177-B1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORP (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-20140296445-A1 | Method For Producing Polydienes And Polydiene Copolymers With Reduced Cold Flow | BRIDGESTONE CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2780177-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | Bridgestone Corporation (JP) | 2014-09-24 | — | — | EP | disclosed |
| CN-104023996-A | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORP | 2014-09-03 | — | — | CN | disclosed |
| WO-2013075074-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORPORATION (JP) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | LMNA 1234/4885MAPT 2042/4885ABCB11 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.